Staff and Wire Article from BioMedReports » profile |
about Staff and Wire Article from BioMedReports
BioMedReports.com is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Content from this website is syndicated througout the world via various news wires and syndicating partners including Market Wire, FinancialContent Services, Inc., United Press Wire and others.
Trading Characteristics
Trading Frequency: Daily
Company
BioMedReports.com is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Content from this website is syndicated througout the world via various news wires and syndicating partners including Market Wire, FinancialContent Services, Inc., United Press Wire and others.
Address:Los Angeles, CA
Tel.:323 472 4480
Website
BioMedReports.com is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Content from this website is syndicated througout the world via various news wires and syndicating partners including Market Wire, FinancialContent Services, Inc., United Press Wire and others.
latest articles
- 1.Continued Uptrend in Vical Shows Promise
- 2.Inovio Receives Top-Notch Results in Monkey Study for Prostate Cancer...
- 3.Echo Therapeutics’ Wireless Glucose-Monitoring System Presents Opportunity in Diabetes Market
- 4.PSID’s Silverman Believes in Upside Potential for his Stock
- 5.Diamyd Closes European Phase III Study; Nuvilex Announces Favorable Pancreatic...
- 6.Buy or Sell? Aastrom Biosciences’s Trial Met Its Primary Safety...
- 7.Merck, Roche Move On Hepatitis C Sales Deal
- 8.Tianyin Shares Soar, Receives Chinese Regulatory Approval for Diabetic Drug
- 9.Shortage of Radioisotopes Threatens Medical Research and Treatment
- 10.Halozyme and ViroPharma in Licensing Deal; Allos Earnings Disappoint
